Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The same ...

In people with no history of CV disease, N-terminal pro-brain natriuretic peptide (NT-proBNP) levels can predict a higher risk of developing CV disease across various blood pressure and pulse pressure ...

In this new subanalysis of data from the Atherosclerosis Risk in the Communities study, investigators assessed the risk of incident heart failure (HF) or death by race and sex, as influenced by ...

Please provide your email address to receive an email when new articles are posted on . Empagliflozin was safe and effective in patients with HF with reduced ejection fraction regardless of systolic ...

Diagnostic thresholds of N-terminal prohormone of brain natriuretic peptide (NT-proBNP) for heart failure with preserved ejection fraction (HFpEF) in ambulatory patients with chronic dyspnearequire ...

Keep reading to learn how biomarker-guided cardioprotection may improve heart outcomes during anthracycline cancer treatment.

Please provide your email address to receive an email when new articles are posted on . Cancer survivors with increased NT-proBNP levels had an elevated risk for all-cause and cardiac mortality.

RARITAN, N.J. -- Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, announced the CE Mark of an enhanced version of its VITROS® NT-proBNP II assay, part of Ortho's expansive cardiac ...